The relationship of serum
phosphate and new-onset
hyperuricemia remains uncertain. We aimed to evaluate the relationship of serum
phosphate with the risk of new-onset
hyperuricemia, and to examine any possible effect modifiers in hypertensive patients. This is a post hoc analysis of the
Uric Acid substudy of the CSPPT (China
Stroke Primary Prevention Trial). A total of 10 612 participants with normal
uric acid levels (<357 μmol/L [6 mg/dL]) at baseline were included in the current study. The primary outcome was new-onset
hyperuricemia, which was defined as a
uric acid concentration ≥417 μmol/L (7 mg/dL) in men or ≥357 μmol/L (6 mg/dL) in women. During a median follow-up of 4.4 years, 1663 (15.7%) participants developed new-onset
hyperuricemia. Overall, there was a significant inverse association between serum
phosphate and the risk of new-onset
hyperuricemia (per SD increment; odds ratio, 0.71; 95% CI, 0.66-0.76). When serum
phosphate was assessed as quartiles, a significantly lower risk of new-onset
hyperuricemia was found in participants in quartile 4 (≥1.4 mmol/L; odds ratio, 0.48; 95% CI, 0.40-0.57) compared with those in quartile 1 (<1.2 mmol/L). Similar results were found in males and females. In summary, there was an inverse association between serum
phosphate and the risk of new-onset
hyperuricemia in hypertensive adults.